Skip to main content
. 2021 Jul 13;374:n1585. doi: 10.1136/bmj.n1585

Table 3.

Ten most common identified screening tool of older person’s prescriptions and screening tool to alert to the right treatment (STOPP/START) criteria of 2331 recommendations made, and implementation at two months

STOPP/START Description No (%)
Count in intervention group Implemented* Not implemented
STOPP
STOPP A1† Any drug prescribed without an evidence based clinical indication 828 (35.5) 428 (51.7) 400 (48.3)
STOPP A3 Any duplicate drug class prescription 147 (6.3) 95 (64.6) 52 (35.4)
STOPP D5 Benzodiazepines for ≥4 weeks 115 (4.9) 45 (39.1) 70 (60.9)
START
START E3 Vitamin D supplement in patients with known osteoporosis and with previous fragility fracture or BMD T scores >−2.0 in multiple sites, or both 96 (4.1) 22 (22.9) 74 (77.1)
START H2 Laxatives in patients receiving opioids regularly 82 (3.5) 12 (14.6) 70 (85.4)
START A6 Angiotensin converting enzyme inhibitor with systolic heart failure or documented coronary artery disease, or both 80 (3.4) 19 (23.8) 61 (76.3)
START E5 Vitamin D supplement in older people who are housebound, experiencing falls, or with osteopenia (BMD T score >−1.0 but <−2.5 in multiple sites) 80 (3.4) 31 (38.8) 49 (61.3)
START E2 Bisphosphonates and vitamin D and calcium in patients taking long term systemic corticosteroid 74 (3.2) 21 (28.4) 53 (71.6)
START E4 Bone antiresorptive or anabolic treatment‡ in patients with documented osteoporosis, where no drug or clinical status contraindication exists (BMD T scores <−2.5 in multiple sites) or history of fragility fracture, or both 71 (3.0) 9 (12.7) 62 (87.3)
START A5 Statin treatment with a documented history of coronary, cerebral, or peripheral vascular disease, unless the patient’s status is end of life or age is >85 years 62 (2.7) 14 (22.6) 48 (77.4)

BMD=bone mineral density.

*

START I1 and I2 criteria and some STRIPA (systematic tool to reduce inappropriate prescribing facilitated by web based STRIP assistant) generated signals that could not be interpreted as implemented recommendations were omitted from analysis.

10 most common identified drug classes with no evidence based indication, in descending order of frequency: antacids, mineral supplements, psychoanaleptics, lipid modifying agents, psychotropics, antithrombotics, vitamin, analgesics (including opioids), laxatives, and drugs for obstructive airway diseases.

For example, bisphosphonate, strontium ranelate, teriparatide, denosumab.